AUROPHARMA Intraday Analysis...
75% Offer Save 9000/- Rs (75% off) on Advance 1000 Plan. Pay Just 3000/- One Year of Intraday Subscription Limited Period Offer.

AUROPHARMA Share Price

Open 1334.80 Change Price %
High 1364.90 1 Day 7.45 0.56
Low 1304.00 1 Week -9.65 -0.71
Close 1342.35 1 Month 183.30 15.81
Volume 1758894 1 Year 791.35 143.62
52 Week High 1432.20
52 Week Low 546.05
AUROPHARMA Important Levels
Resistance 2 1398.80
Resistance 1 1375.54
Pivot 1337.08
Support 1 1309.16
Support 2 1285.90
AUROPHARMA CURRENT MONTH FUTURE
Close 1344.95
Contracts Traded 19711
Open Intrest 8891500
Change In O.I -490750
Lot Size 250
AUROPHARMA CURRENT MONTH OPTION
Most Active Call 1400
Most Active put 1300
Highest O.I Buildup Call 1400
Highest O.I Buildup Put 1300
Expiry Date 30-Apr-2015
AUROPHARMA ALL MONTHS OPTIONS
For All AUROPHARMA Options Click Here
NSE INDIA Most Active Stocks
NIFTY 8448.10 -1.83%
UNITECH 16.45 -2.37%
SUZLON 26.40 -4.52%
HDIL 117.55 -9.30%
CNXIT 11562.20 -2.04%
GMRINFRA 16.50 -4.07%
JPASSOCIAT 24.10 -2.03%
SBIN 287.65 -1.41%
ICICIBANK 311.15 0.34%
ASHOKLEY 70.65 -3.15%
More..
NSE INDIA Top Gainers Stocks
FCSSOFT 0.30 20.00%
IOLCP 34.70 19.86%
ROHLTD 55.95 18.92%
NICCO 0.65 18.18%
BILENERGY 1.15 15.00%
CANTABIL 70.75 14.95%
CLNINDIA 986.35 14.39%
KSERASERA 0.40 14.29%
VASWANI 3.40 13.33%
SHIRPUR-G 76.45 12.59%
More..
NSE INDIA Top Losers Stocks
MANAKALUCO 8.55 -19.34%
MANAKINDST 10.95 -18.28%
MANAKCOAT 8.70 -16.75%
BLUECHIP 0.25 -16.67%
SRGINFOTEC 0.30 -14.29%
ONELIFECAP 87.10 -12.90%
PROVOGE 6.15 -10.87%
MEGH 16.50 -10.08%
ZENITHBIR 0.90 -10.00%
UBHOLDINGS 22.65 -9.94%
More..

Aurobindo Pharma Limited (NSE: AUROPHARMA)

AUROPHARMA Technical Analysis 5
As on 20th Apr 2015 AUROPHARMA Share Price closed @ 1342.35 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 950.56 & Strong Buy for SHORT-TERM with Stoploss of 1174.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
AUROPHARMA Target for April
1st Target up-side 1344.77
2nd Target up-side 1431.1
3rd Target up-side 1517.43
1st Target down-side 1098.43
2nd Target down-side 1012.1
3rd Target down-side 925.77
AUROPHARMA Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 68.32 Sideways
MFI (14) MFI is 54.52 Sideways
CCI (20) CCI is -13.16 Sideways
WILLIAM %R (14) William %R is -42.53 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 658.30
10 Day Avg Volume Traded 16.95 % More then 10 Day Average Volume
AUROPHARMA Other Details
Segment EQ
Market Capital 25150871552.00
Sector Pharmaceuticals
Industry
Offical website
AUROPHARMA Address
AUROPHARMA
N/A
AUROPHARMA Latest News
Interactive Technical Analysis Chart Aurobindo Pharma Limited ( AUROPHARMA NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Aurobindo Pharma Limited
AUROPHARMA Business Profile
Aurobindo Pharm is in the Pharmaceuticals sector. Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others. Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India. The current market capitalisation stands at Rs 8,284.96 crore.The company has reported a consolidated sales of Rs 1913.86 crore and a Net Profit of Rs 233.86 crore for the quarter ended Sep 2013. The company management includes K Ragunathan - Non Executive Chairman, K Nithyananda Reddy - Vice Chairman & Whole Time Dir, N Govindarajan - Managing Director, M Sivakumaran - Whole Time Director, M Madan Mohan Reddy - Whole Time Director, P V Ramprasad Reddy - Non Executive Director, P Sarath Chandra Reddy - Non Executive Director, M Sitarama Murthy - Non Executive Director, D Rajagopala Reddy - Non Executive Director, C Channa Reddy - Non Executive Director. It is listed on the BSE with a BSE Code of 524804 and the NSE with an NSE Code of AUROPHARMA. Its Registered office is at Plot No. 2, Maitrivihar,,Ameerpet Hyderabad,Andhra Pradesh - 500038.